 |
110 Diseases |  |
151 Trials |
|
151 Trials |  |
7120 News |  |
| «12...75767778798081828384858687» |
- |||||||||| Prolia (denosumab) / Amgen, Daiichi Sankyo
New P3 trial: Denosumab China Phase III Study (clinicaltrials.gov) - Dec 16, 2013
P3, N=444, Recruiting, Sponsor: GlaxoSmithKline
- || Prolia (denosumab) / Amgen, Daiichi Sankyo
Trial initiation date: Observational Study of Denosumab (Prolia (clinicaltrials.gov) - Dec 15, 2013
P=N/A, N=1501, Active, not recruiting, Sponsor: Amgen
Initiation date: Nov 2011 --> Nov 2012
- || Prolia (denosumab) / Amgen, Daiichi Sankyo
Enrollment change: Observational Study of Denosumab (Prolia (clinicaltrials.gov) - Dec 15, 2013
P=N/A, N=1501, Active, not recruiting, Sponsor: Amgen
Initiation date: Nov 2011 --> Nov 2012 N=1200 --> 1501
- || Prolia (denosumab) / Amgen, Daiichi Sankyo
Enrollment closed: Observational Study of Denosumab (Prolia (clinicaltrials.gov) - Dec 15, 2013
P=N/A, N=1501, Active, not recruiting, Sponsor: Amgen
N=1200 --> 1501 Recruiting --> Active, not recruiting
- || Prolia (denosumab) / Amgen, Daiichi Sankyo
Enrollment closed: Prospective Observational Study to Describe Characteristics and Management of Patients Treated With Denosumab (Prolia (clinicaltrials.gov) - Dec 15, 2013
P=N/A, N=600, Active, not recruiting, Sponsor: Amgen
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- |||||| Prolia (denosumab) / Amgen, Daiichi Sankyo
Enrollment open: AMG 162 (Denosumab) Phase 3 Study (DESIRABLE Study) in Participants With Rheumatoid Arthritis on Disease-modifying Antirheumatic Drugs (DMARDs) Treatment (clinicaltrials.gov) - Dec 1, 2013
P3, N=642, Recruiting, Sponsor: Daiichi Sankyo Inc.
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
Trial completion: Multiple Dose Study to Evaluate the Safety of Multiple Doses of Denosumab 120 mg in Adults With Severe Chronic Kidney Disease (CKD) and CKD on Dialysis (clinicaltrials.gov) - Nov 25, 2013
P1, N=32, Completed, Sponsor: Amgen
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- ||||||| Prolia (denosumab) / Amgen
Trial completion, Adherence: Denosumab Adherence Preference Satisfaction Study (clinicaltrials.gov) - Nov 18, 2013
P3, N=250, Completed, Sponsor: Amgen
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
New P2 trial: Denosumab Administration After Spinal Cord Injury (clinicaltrials.gov) - Nov 12, 2013
P2, N=24, Not yet recruiting, Sponsor: Department of Veterans Affairs
- Prolia (denosumab) / Amgen, Daiichi Sankyo, Samcyprone (diphenylcyclopropenone) / Phio Pharma
Enrollment open, IO biomarker: Effect of RANKL Inhibition on UV-induced Immunosuppression (clinicaltrials.gov) - Nov 6, 2013
P1, N=30, Recruiting, Sponsor: Innovaderm Research Inc.
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Prolia (denosumab) / Amgen, Daiichi Sankyo, Samcyprone (diphenylcyclopropenone) / Phio Pharma
New P1 trial, IO biomarker: Effect of RANKL Inhibition on UV-induced Immunosuppression (clinicaltrials.gov) - Nov 5, 2013
P1, N=30, Recruiting, Sponsor: Innovaderm Research Inc.
- |||||||||| Prolia (denosumab) / Amgen, Daiichi Sankyo
New P3 trial: AMG 162 (Denosumab) Phase 3 Study (DESIRABLE Study) in Participants With Rheumatoid Arthritis on Disease-modifying Antirheumatic Drugs (DMARDs) Treatment (clinicaltrials.gov) - Oct 29, 2013
P3, N=642, Recruiting, Sponsor: Daiichi Sankyo Inc.
- Prolia (denosumab) / Amgen, Daiichi Sankyo
Enrollment open: Acute Effect of Teriparatide With Bisphosphonate or Denosumab on Bone Resorption (clinicaltrials.gov) - Oct 21, 2013
P4, N=40, Recruiting, Sponsor: Massachusetts General Hospital
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||| zoledronic acid / Generic mfg.
Adverse events: Osteonecrosis of the Jaw (ONJ) and Infection Among Nordic Cancer Patients Treated With XGEVA (clinicaltrials.gov) - Oct 20, 2013
P=N/A, N=3600, Active, not recruiting, Sponsor: Amgen
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
Biomarker, New P2 trial: Denosumab for Breast Cancer With Bone Mets (clinicaltrials.gov) - Sep 25, 2013
P2, N=35, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
- ||||| Prolia (denosumab) / Amgen
New P2 trial, Combination therapy, Metastases: Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer (clinicaltrials.gov) - Sep 24, 2013
P2, N=216, Recruiting, Sponsor: Amgen
- Prolia (denosumab) / Amgen
Enrollment open, IO biomarker: D-Beyond: A Study to Evaluate Denosumab in Young Patients With Primary Breast Cancer (clinicaltrials.gov) - Sep 3, 2013
P2, N=39, Recruiting, Sponsor: Jules Bordet Institute
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Prolia (denosumab) / Amgen, Daiichi Sankyo
Enrollment closed: Treatment of Atraumatic Bone Marrow Edema With Denosumab and Teriparatide vs Placebo (clinicaltrials.gov) - Aug 26, 2013
P4, N=90, Active, not recruiting, Sponsor: Medical University of Vienna
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- ||||||| Prolia (denosumab) / Amgen, Daiichi Sankyo
Trial completion: A Multi-Center, Randomized, Open-Label Study to Assess the Immunogenicity and Safety of Denosumab in Pre-filled Syringe Compared to Vial in Subjects With Low Bone Mineral Density (clinicaltrials.gov) - Aug 26, 2013
P3, N=311, Completed, Sponsor: Amgen
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
New P4 trial: ProliaHip: Denosumab in Enhancement of Bone Bonding of Hip Prosthesis in Postmenopausal Women (clinicaltrials.gov) - Aug 18, 2013
P4, N=68, Recruiting, Sponsor: Turku University Hospital
- |||||||||| Prolia (denosumab) / Amgen, Daiichi Sankyo
New P3 trial: A Study to Compare Denosumab With Zoledronic Acid in Subjects With Bone Metastases From Solid Tumors (clinicaltrials.gov) - Aug 8, 2013
P3, N=477, Not yet recruiting, Sponsor: GlaxoSmithKline
- ||||||| Prolia (denosumab) / Amgen, Daiichi Sankyo
Trial completion: A Study in Indian Postmenopausal Women With Osteoporosis to Evaluate the Efficacy and Safety of Denosumab (clinicaltrials.gov) - Aug 7, 2013
P3, N=250, Completed, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||||| Prolia (denosumab) / Amgen, Daiichi Sankyo
Trial completion: A Study in Korean Postmenopausal Women With Osteoporosis to Evaluate the Efficacy and Safety of Denosumab (clinicaltrials.gov) - Aug 7, 2013
P3, N=135, Completed, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||||| Prolia (denosumab) / Amgen
Trial completion, Metastases: AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Aromatase Inhibitor Therapy for Non-metastatic Breast Cancer (clinicaltrials.gov) - Jul 22, 2013
P3, N=252, Completed, Sponsor: Amgen
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Prolia (denosumab) / Amgen
Biomarker, New P2 trial: Can treatment with drugs developed to treat thin and weakened osteoporotic bones make knee implants stay fixed in the bones and last longer? (EUDRACT) - Jul 2, 2013
P2, N=100, Ongoing, Sponsor: ORtop
- |||| Prolia (denosumab) / Amgen, Daiichi Sankyo
Enrollment open: Study of Denosumab in Subjects With Giant Cell Tumor of Bone (clinicaltrials.gov) - Jun 26, 2013
P2, N=530, Recruiting, Sponsor: Amgen
Active, not recruiting --> Completed Active, not recruiting --> Recruiting
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
New P1 trial: Study to Evaluate the Concentration of Denosumab in Seminal Fluid in Healthy Men After a Single Subcutaneous Dose (clinicaltrials.gov) - Jun 3, 2013
P1, N=12, Completed, Sponsor: Amgen
- Prolia (denosumab) / Amgen
New P2 trial, IO biomarker: D-Beyond: A Study to Evaluate Denosumab in Young Patients With Primary Breast Cancer (clinicaltrials.gov) - May 28, 2013
P2, N=39, Recruiting, Sponsor: Jules Bordet Institute
- ||| Prolia (denosumab) / Amgen, Daiichi Sankyo
New P3 trial: Denosumab for Prolonging Bone Metastasis-Free Survival in Men With Hormone-Refractory Prostate Cancer (clinicaltrials.gov) - Apr 2, 2013
P3, N=18, Active, not recruiting, Sponsor: Amgen
- Prolia (denosumab) / Amgen, Daiichi Sankyo
New P2 trial: Translational Therapy in Patients With Osteogenesis Imperfecta - A Pilot Trial on Treatment With the Rankl-Antibody Denosumab (clinicaltrials.gov) - Feb 25, 2013
P2, N=10, Active, not recruiting, Sponsor: University of Cologne
- |||||| Prolia (denosumab) / Amgen
Enrollment open: Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma (clinicaltrials.gov) - Feb 17, 2013
P3, N=1520, Recruiting, Sponsor: Amgen
Active, not recruiting --> Recruiting Ongoing --> Recruiting
- ||||| Prolia (denosumab) / Amgen
Enrollment closed: Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE) (clinicaltrials.gov) - Jan 24, 2013
P3, N=4509, Active, not recruiting, Sponsor: Amgen
Ongoing --> Recruiting Recruiting --> Active, not recruiting
- Prolia (denosumab) / Amgen, Daiichi Sankyo
New P4 trial: RA Denosumab on Bone Microstructure Study (clinicaltrials.gov) - Jan 15, 2013
P4, N=40, Not yet recruiting, Sponsor: Chinese University of Hong Kong
- Prolia (denosumab) / Amgen, Daiichi Sankyo
Trial completion, Head-to-Head: DenoZol: Comparative Effect of Zoledronic Acid Versus Denosumab on Serum Sclerostin of Postmenopausal Women With Low Bone Mass (clinicaltrials.gov) - Jan 14, 2013
P=N/A, N=91, Completed, Sponsor: Aristotle University Of Thessaloniki
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Prolia (denosumab) / Amgen, Daiichi Sankyo
New P4 trial: Bone anchored femoral amputation prostheses - Denusomab Trial (EUDRACT) - Jan 3, 2013
P4, N=14, Ongoing, Sponsor: Ortop
- ||||| Prolia (denosumab) / Amgen, Daiichi Sankyo
New P4 trial: Effects of Teriparatide or Denosumab on Bone in Postmenopausal Women With Osteoporosis (clinicaltrials.gov) - Dec 18, 2012
P4, N=68, Active, not recruiting, Sponsor: Eli Lilly and Company
- Prolia (denosumab) / Amgen, Daiichi Sankyo
New P4 trial: Acute Effect of Teriparatide With Bisphosphonate or Denosumab on Bone Resorption (clinicaltrials.gov) - Dec 13, 2012
P4, N=40, Recruiting, Sponsor: Massachusetts General Hospital
- Prolia (denosumab) / Amgen, Daiichi Sankyo
Enrollment open: Effect of Denosumab on Inflammatory Osteolytic Lesion Activity in Total Hip Arthroplasty (clinicaltrials.gov) - Dec 13, 2012
P2, N=30, Recruiting, Sponsor: Sheffield Teaching Hospitals NHS Foundation Trust
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
New P4 trial: Treatment of Atraumatic Bone Marrow Edema With Denosumab and Teriparatide vs Placebo (clinicaltrials.gov) - Nov 26, 2012
P4, N=90, Active, not recruiting, Sponsor: Medical University of Vienna
- ||||| Prolia (denosumab) / Amgen
New P4 trial: Safety and Efficacy Study to Evaluate Denosumab Compared With Zoledronic Acid in Postmenopausal Women With Osteoporosis (clinicaltrials.gov) - Nov 22, 2012
P4, N=643, Active, not recruiting, Sponsor: Amgen
- Prolia (denosumab) / Amgen
Trial initiation date, Tumor cell: Pilot Study to Evaluate the Impact of Denosumab on Disseminated Tumor Cells (DTC) in Patients With Early Stage Breast Cancer (clinicaltrials.gov) - Nov 13, 2012
P2, N=45, Recruiting, Sponsor: Hope Rugo, MD
Not yet recruiting --> Recruiting Initiation date: Jun 2012 --> Nov 2012
- Prolia (denosumab) / Amgen
Enrollment open, Tumor cell: Pilot Study to Evaluate the Impact of Denosumab on Disseminated Tumor Cells (DTC) in Patients With Early Stage Breast Cancer (clinicaltrials.gov) - Nov 13, 2012
P2, N=45, Recruiting, Sponsor: Hope Rugo, MD
Initiation date: Jun 2012 --> Nov 2012 Not yet recruiting --> Recruiting
- ||||||| Prolia (denosumab) / Amgen
Trial completion: Study to Compare the Efficacy and Safety of DenosumAb Versus Placebo in Males With Osteoporosis (clinicaltrials.gov) - Oct 28, 2012
P3, N=242, Completed, Sponsor: Amgen
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- ||||||| Prolia (denosumab) / Amgen, Daiichi Sankyo
Trial completion: Study to Evaluate the Safety and Efficacy of Denosumab and Actonel (clinicaltrials.gov) - Oct 28, 2012
P3, N=870, Completed, Sponsor: Amgen
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||||| Prolia (denosumab) / Amgen, Daiichi Sankyo
Trial completion: An Open-label, Single-arm Extension Study to Evaluate the Long-term Safety of Denosumab Administration in Postmenopausal Women With Low Bone Mineral Density (clinicaltrials.gov) - Oct 16, 2012
P3, N=200, Completed, Sponsor: Amgen
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||||| Prolia (denosumab) / Amgen
Trial completion: A Study to Evaluate the Safety and Efficacy of Denosumab and Ibandronate in Postmenopausal Women Sub-Optimally Treated With Daily or Weekly Bisphosphonates (clinicaltrials.gov) - Sep 18, 2012
P3, N=833, Completed, Sponsor: Amgen
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||||| Prolia (denosumab) / Amgen
Trial completion, Metastases: Extension Study to Evaluate Long Term Safety of Denosumab in Subjects Undergoing ADT for Non-Metastatic Prostate Cancer (clinicaltrials.gov) - Aug 7, 2012
P3, N=384, Completed, Sponsor: Amgen
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||||| Prolia (denosumab) / Amgen, Daiichi Sankyo
Trial completion: DIRECT: Denosumab Fracture Intervention Randomized Placebo Controlled Trial in Japanese Patients With Osteoporosis (clinicaltrials.gov) - Jul 16, 2012
P3, N=1262, Completed, Sponsor: Daiichi Sankyo Co., Ltd.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
New P2 trial: Effects of Denosumab on Periprosthetic Bone After Total Hip Arthroplasty (clinicaltrials.gov) - Jun 26, 2012
P2, N=64, Recruiting, Sponsor: Hans Mallmin
- Prolia (denosumab) / Amgen, Kineret (anakinra) / SOBI
New P1 trial, Combination therapy, Metastases: NCI-2018-01842: Everolimus and Anakinra or Denosumab in Treating Participants With Relapsed or Refractory Advanced Cancers (clinicaltrials.gov) - Jun 19, 2012
P1, N=147, Recruiting, Sponsor: M.D. Anderson Cancer Center